Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
CA 2483285 C · Owner: Esbatech, A Novartis Company Llc · Inventors: Escher, Dominik; Ewert, Stefan; Tissot, Kathrin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 21, 2003 and granted January 27, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.